Vera Therapeutics’ Ataccept Shows Promise for Long-Term IgAN Treatment: Positive Data From Phase 2b Trial

Vera Therapeutics announced positive long-term data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), showcasing stabilized kidney function and a favorable safety profile. The results, presented at Kidney Week 2024 and published in the Journal of the American Society of Nephrology, further support the potential of atacicept as a long-term IgAN treatment and bolster confidence in the ongoing Phase 3 trial. The company is also planning to initiate an extension study to provide continued access to atacicept before commercial availability.

Scroll to Top